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Sex difference in clot lysability and
association to coronary artery calcification
Ramshanker Ramanathan1,2,3,4* , Niels Peter R. Sand1,2, Johannes J. Sidelmann3,4, Bjarne L. Nørgaard5
and Jørgen B. Gram3,4
Abstract
Background: Incidence and prevalence of cardiovascular disease (CVD) differ between sexes, and women
experience CVD later than men. Changes in fibrin clot lysability are associated with CVD, and the present
study addresses sex differences in fibrin clot lysability in asymptomatic middle-aged individuals and the
relation to coronary artery calcification (CAC).
Methods: Participants free of morbidities and medication, N = 163, were randomly chosen from a national registry
among citizens, 50 or 60 years of age, and were followed for 5 years. CAC was determined by the Agatston (Ag) score
both at baseline and at follow-up. Based on the changes in Ag, the population was divided into two groups: ΔAg =
0 U or ΔAg > 0 U. Fibrin clot analyses were based on turbidimetric methods.
Results: At baseline, 116 women and 97 men were included; 84 women and 79 men completed the 5-year
follow-up (77%). Independently of covariates, women with ΔAg > 0 had reduced mean (SD) fibrin lysability at
follow-up, 40.2% (15.9), both in comparison to baseline, 47.8% (20.4), p = 0.001, to women with ΔAg = 0 U, 51.
2% (24.5), p = 0.028, and to men with ΔAg > 0 U, 54.4% (21.0), p = 0.002.
Conclusions: Fibrin clot lysability changes over time with considerable sex differences. Women with progression of
CAC have reduced fibrin clot lysability compared to men, indicating a sex-specific association between morphological
vessel wall changes and fibrin clot lysability.
Keywords: Sex difference, Cardiovascular disease, Coronary artery calcification, Fibrin clot lysability
Background
The incidence and prevalence of cardiovascular disease
(CVD) differ between sexes, and women experience
CVD later than men [1]. These epidemiological observa-
tions have been the fundament for studies searching for
sex differences in biochemical [2] and morphological [3]
characteristics in the subclinical phase of the disease.
The preponderance of studies have shown that premeno-
pausal women have a favorable lipid profile, lower blood
pressure levels, and less coronary artery calcification (CAC)
compared with age-matched men [4, 5]. After the meno-
pause the condition changes towards alignment with the
age-dependent changes observed in men [6], probably due
to the lack of the protecting effects of estrogens in post-
menopausal women [7, 8]. Studies have indicated that
although the debut of CVD is postponed, the short-term
mortality after myocardial infarction (MI) is higher in
women younger than 75 years old than in age-matched
men [9]. The causes of these findings are unclear [10], but
fibrin may in this context play an important role, as it is a
matrix for tissue repair and has been shown to contribute
to plaque growth in a multitude of ways [11–13]. Therefore,
it might be of relevance to explore alterations in fibrin clot
lysability in relation to development of CAC as a surrogate
marker of CVD.
More than two decades ago, Fatah et al. observed a con-
nection between abnormal fibrin architecture in men with
MI compared to healthy controls [14]. Since then, studies
have elaborated the link between CVD and altered fibrin
structure and clot lysability in different patient categories
[15–19]. Most of these studies have shown that defect
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fibrin clot lysability is associated with the evolution of
CVD [15, 17, 20, 21]. However, sex differences in fibrin
clot lysability have not been thoroughly evaluated, and the
relation to coronary atherosclerosis is still speculative.
Consequently, in the present cross-sectional cohort
study, we examined sex differences and changes over
time in fibrin clot lysability in asymptomatic middle-
aged individuals. Furthermore, we addressed the poten-
tial association between fibrin clot lysability and CAC.
Methods
Study design and participants
This cross-sectional cohort study with follow-up recruiting
participants from the Danish Risk Score (DanRisk) study
[22] was performed at four hospitals (Svendborg, Odense,
Vejle, and Esbjerg) in Southern Denmark from 2009 to
2010. Study participants were randomly chosen from the
Danish Central Person Registry among citizens born either
in 1949 or 1959. The present study focuses on participants
recruited from Esbjerg [23]. In brief, 458 participants were
invited at baseline, of whom 329 (72%) accepted the invita-
tion. After exclusion of individuals with symptomatic CVD
(angina, myocardial infarction, treatment with percutaneous
coronary revascularization or coronary by-pass surgery),
atrial fibrillation, stroke, peripheral artery disease, heart
valve disease, and diabetes or taking any kind of medication,
a total of 213 (47%) comprised the study population at
baseline. After 5 years, all 213 participants were re-invited
to a follow-up assessment, and 163 (77%) participants were
re-examined and thus constituted the final population.
Prior to examination, the participants filled in a ques-
tionnaire concerning medical history, family history with
CVD, and smoking habits. In addition, participants were
interviewed about the same topics. Physical examination
included BMI calculations based on measurements of
height and weight, waist circumference, blood pressure
and pulse (average of three measurements after 5 min of
rest), and an ECG.
Cardiac CT
All CT scans both at baseline and at follow-up were ana-
lyzed by the same experienced cardiologist, who was
blinded to all other patient data. CAC was expressed as
Agatston (Ag) score [24]. The internal validity of the cal-
cium scoring was high [22]. Non-contrast scan data were
acquired during an inspiratory breath hold.
Ag at baseline was assessed by a Toshiba 64-slice CT-
scanner (Aquilion, Toshiba Medical Systems). The follow-
ing technical settings were used: gantry rotation time
450 ms, collimation 64 × 0.5 mm, slice thickness 3 mm,
120 kV tube voltage, 240 mA tube current, and prospective
gating at 75% of the R-R interval. At follow-up, Ag was
assessed using a Philips 64-slice scanner (Brilliance 64,
Philips Healthcare). The following technical settings were
used: gantry rotation time 400 ms, collimation 64 ×
0.625 mm, slice thickness 2.5 mm, 120 kV tube voltage,
220 mA tube current, and prospective gating at 75% of
the R-R interval. The mean (SD, range, k-factor) estimated
radiation dose at baseline was 1.36 mSv (0.54, 0.49–
3.06 mSv, 0.0145), and the mean (SD, range, k-factor)
estimated radiation dose at follow-up was 1.09 mSv (0.31,
0.48–2.22 mSv, 0.0145).
The study population was separated into two groups
based on the numeric difference between Ag at follow-
up and baseline: ΔAg = 0 U or ΔAg > 0 U.
Blood collection and handling
Blood samples were drawn from an antecubital vein into
sterile vacuum plastic tubes containing either 0.109 mol/L
citrate or no anticoagulants, and the plasma or serum iso-
lated after 20 min of centrifugation at 2000g at 20 °C were
frozen and stored in aliquots at − 80 °C until analysis.
Biochemical analysis
Lipids were analyzed using Cholesterol, Direct LDL, Ultra
HDL, and Triglycerides kits employing the Architect
C16000 analyzer. Kits and analyzer were from Abbott,
Wiesbaden, Germany. Concentrations of CRP and fibrino-
gen were determined on a BN-II nephelometer using anti-
bodies and reagents from Siemens Healthcare Diagnostics
GmbH, Marburg, Germany. Plasminogen activator inhibitor
type 1 (PAI-1) antigen, was quantitatively determined by a
sandwich enzyme immunoassay (ELISA) using in-house
specific antibodies as previously described [25] employing a
microplate reader (Tecan Trading AG, Basle, Switzerland).
Fibrin clot lysis was recorded using turbidity measure-
ments as previously described [20]. In brief, citrate-
stabilized plasma was mixed with thrombin, CaCl2, and
Tween 80 and incubated overnight in a microtiter plate
sealed with adhesive tape. All clots were made in duplicate.
To initiate fibrinolysis, t-PA and flufenamic acid were added
onto the clots. The 405-nm optical density (OD) was then
followed on a Sunrise plate reader (Tecan Austria, Grödig/
Salzburg, Austria) every 5 min for 4 h at 25 °C. The rate of
fibrinolysis per hour was determined from the slope of the
curve at the time when the slope became constant and was
normalized with respect to the maximum absorbency value
before lysis initiation.
Statistics
Continuous variables are presented as means and standard
deviations (SD) or median and interquartile ranges (IQR)
as appropriate. Normality was examined by the Shapiro-
Wilk test as well as by visually assessing histograms and
Q-Q plots. If possible, non-normally distributed variables
were log-transformed to achieve normality. Dichotomous
variables are shown as numbers and percentages. Student’s
t test was used for comparison of normally distributed
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continuous variables and the Mann-Whitney test for com-
parison of non-normally distributed continuous variables.
The χ2 test was performed for comparison of dichotomous
variables. The paired Student’s t test was used for paired
comparison of normally distributed continuous variables,
and the Wilcoxon signed rank test was used for paired
comparison of non-normally distributed continuous vari-
ables. p values < 0.05 were considered statistically signifi-
cant. Covariates were identified as variables which were
significantly different between the sexes in the univariate
analyses and correlated with fibrin clot lysability using the
Spearman correlation test. A linear regression model using
fibrin clot lysability as the dependent variable was created,
and the model was adjusted for identified covariates. To
ensure model validation, Q-Q plots for residuals were
inspected for normality. Stata 15.0, StataCorp, TX, USA,
was used for statistical analyses.
Results
Baseline and follow-up characteristics
Participants were followed for a mean (range) of 5.5 years
(5.2–5.7 years). At baseline, 116 women and 97 men were
included and 84 women and 79 men completed the follow-
up. Study population characteristics at baseline and follow-
up are shown in Tables 1 and 2. Women had lower levels of
systolic and diastolic blood pressures, lower levels of triglyc-
erides, higher high-density lipoprotein (HDL) cholesterol
levels, and lower Ag compared to men (all p < 0.05) both at
baseline and follow-up, while C-reactive protein (CRP) was
comparable between men and women. Body mass index
(BMI) was lower in women at baseline (p= 0.039) but
comparable among men and women at follow-up, while
fibrinogen was higher in women at baseline (p= 0.008) and
comparable among men and women at follow-up. ΔAg was
significantly lower in women than in men (p= 0.012). ΔAg
= 0 U was observed in 85 participants (53 women). ΔAg
> 0 U was observed in 78 participants (31 women); of these,
23 participants (10 women) had ΔAg= 1–10 U, 35 partici-
pants (12 women) had ΔAg= 11–100, and 20 participants
(9 women) had ΔAg > 100 U. Negative ΔAg observed in
eight participants was classified as ΔAg= 0 U.
Fibrin clot lysability
Women with ΔAg > 0 U had reduced mean (SD) clot
lysability at follow-up compared to baseline, 40.2%
(15.9) versus 47.8% (20.4) (p = 0.001) (Fig. 1). There
was no difference in clot lysability between baseline
and follow-up in women with ΔAg > 0 U or in men.
As shown in Figs. 2 and 3, at follow-up, women with
ΔAg > 0 U had reduced mean (SD) clot lysability,
40.2% (15.9), compared to men with ΔAg > 0 U,
54.4% (21.0) (p = 0.002), and compared to women with
ΔAg = 0 U, 51.2% (24.5) (p = 0.028). No difference in
fibrin clot lysability between men with ΔAg = 0 U
and ΔAg > 0 U was observed. Only triglycerides
(r = − 0.168, p = 0.032), fibrinogen (r = − 0.444, p < 0.001),
and PAI-1 (r = − 0.223, p = 0.004) correlated with fibrin
clot lysability. Adjusting for the confounding effect of
Table 1 Study population characteristics at baseline
Baseline, N = 163 Men (n = 79) Women (n = 84) p value
Born
1949 (n = 70) 30 (43) 40 (57)
1959 (n = 93) 49 (53) 44 (47) 0.21
Tobacco use
Never (n =77) 35 (45) 42 (55)
Prior/current (n = 86) 44 (51) 42 (49) 0.53
Systolic blood pressure, mmHg
Diastolic blood pressure, mmHg
140 (15)
82 (9)
132 (19)
78 (9)
0.007
0.002
Body mass index, kg/m2 27.4 (3.6) 26.1 (4.6) 0.039
Agatston score, U 0 (0–33) 0 (0–7) 0.012
Total cholesterol, mmol/l
LDL cholesterol, mmol/l
HDL cholesterol, mmol/l
Triglycerides, mmol/l
5.42 (0.97)
3.34 (0.82)
1.26 (1.02–1.54)
1.47 (0.80)
5.54 (1.07)
3.23 (0.91)
1.52 (1.35–1.85)
1.14 (0.60)
0.44
0.39
< 0.001
0.003
C-reactive protein, mg/l 0.74 (0.36–1.61) 0.72 (0.29–1.86) 0.67
Fibrinogen, μmol/l 8.9 (7.9–9.9) 9.6 (8.5–10.9) 0.008
PAI-1, ng/ml 16.5 (11.2–24.4) 12.5 (6.7–20.2) 0.016
Fibrin clot lysability, % 54.8 (19.7) 51.5 (22.2) 0.32
Values are presented as mean (SD), median (IQR), or number (%). Information on C-reactive protein is missing on three participants. Information on PAI-1 is
missing on four participants
LDL low-density lipoprotein, HDL high-density lipoprotein, PAI-1 plasminogen activator inhibitor type 1
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fibrinogen, triglycerides, and PAI-1 showed that the
observed reduced fibrin clot lysability in women with
ΔAg > 0 U compared to women with ΔAg = 0 U and men
with ΔAg > 0 U was independent of covariation (p = 0.028
and p = 0.013, respectively).
Discussion
In the present prospective cross-sectional cohort study,
comprising apparently healthy middle-aged individuals,
we demonstrate significantly reduced fibrin clot lysability
during a 5-year follow-up in women with progression of
Table 2 Study population characteristics at follow-up
Follow-up, N = 163 Men (n = 79) Women (n = 84) p value
Born
1949 (n = 70) 30 (43) 40 (57)
1959 (n = 93) 49 (53) 44 (47) 0.21
Tobacco use
Never (n = 76) 34 (45) 42 (55)
Prior/current (n = 87) 45 (52) 42 (48) 0.47
Systolic blood pressure, mmHg
Diastolic blood pressure, mmHg
140 (17)
81 (8)
133 (16)
72 (9)
0.013
< 0.001
Body mass index, kg/m2 28.1 (4.2) 26.9 (4.7) 0.063
Agatston score, U 9 (0–115) 0 (0–26) 0.002
ΔAgatston score, U 4 (0–49) 0 (0–10) 0.012
Total cholesterol, mmol/l
LDL cholesterol, mmol/l
HDL cholesterol, mmol/l
Triglycerides, mmol/l
5.31 (0.85)
3.33 (0.80)
1.30 (1.10–1.40)
1.82 (0.97)
5.54 (0.92)
3.30 (0.93)
1.55 (1.40–1.75)
1.50 (0.89)
0.10
0.80
< 0.001
0.032
C-reactive protein, mg/l 0.74 (0.46–1.61) 0.70 (0.30–2.18) 0.74
Fibrinogen, μmol/l 8.9 (7.7–10.3) 9.5 (8.4–11.1) 0.056
PAI-1, ng/ml 21.7 (15.4–27.5) 20.1 (15.0–30.3) 0.69
Fibrin clot lysability, % 52.1 (20.5) 47.2 (22.3) 0.14
Values are presented as mean (SD), median (IQR), or number (%). Information on Agatston score is missing on one participant
LDL low-density lipoprotein, HDL high-density lipoprotein, PAI-1 plasminogen activator inhibitor type 1
Fig. 1 Clot lysability in women with ΔAgatston score > 0 U at
baseline and follow-up (N = 31). Variables are compared using the
paired Student’s t test. Mean and SD are indicated in bars
Fig. 2 Clot lysability in men (N = 47) and women (N = 31) with
ΔAgatston score > 0 U at follow-up. Variables are compared using
the unpaired Student’s t test. Mean and SD are indicated in bars
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CAC. Furthermore, women with progression of CAC
had reduced clot lysability compared to men as well as
compared to women without progression of CAC, as
these subgroups had no significant alterations in clot
lysability over time. These findings were independent of
confounding covariates.
Although several hypotheses have been suggested as
the potential cause for sex differences in the natural his-
tory of CVD, basic mechanisms are still unknown. In this
perspective, a positive correlation between high fibrino-
gen levels in young adulthood and incidence of CAC later
in life has been reported in the Coronary Artery Risk
Development in Young Adults (CARDIA) study [13], and
other studies have reported an association between high
fibrinogen levels and thrombosis [26]. In general, women
have higher plasma concentration of fibrinogen than age-
matched men [27], and fibrinogen as a precursor of fibrin
is considered to be an important determinant of the fibrin
structure [28]. A prothrombotic effect of increased
fibrinogen is probably closely linked to alterations in
fibrin structure [29, 30] causing fibrin to be more resist-
ant to lysis. In the present study, we observed differences
in fibrinogen concentrations between sexes at baseline
but not at follow-up, and although the fibrinogen concen-
tration correlated with clot lysability, the sex-related
differences in clot lysability remained significant after
adjustment for the potential confounding effect of
fibrinogen. These findings indicate that other factors than
fibrinogen are responsible for the observed differences in
fibrin clot lysability.
We have previously shown that women with atrial
fibrillation differ in fibrin polymerization characteristics
compared to men [18] and that women receiving OC
have alterations in fibrin structure and increased clot
lysability [31]. Moreover, middle-aged women receiving
estrogen therapy have a reduced burden of CAC com-
pared to women receiving placebo [32]. We therefore
hypothesize that the reduced wall repair mechanisms
and increasing CAC observed in women after meno-
pause [8] may partly be due to altered fibrin lysability.
Thus, a reduction of more than 20% in fibrin clot lysa-
bility recorded in women with CAC progression may
contribute to the different cardiovascular pathophysi-
ology observed in women after the menopause.
In addition, clinical studies suggest that fibrinogen and
fibrin deposits in atherosclerotic plaques, and not circu-
lating fibrinogen, contribute to plaque growth and stabil-
ity by stimulating migration and proliferation of smooth
muscle cells as well as creating a matrix for the calcium
deposits in the growing plaque [11–13]. As both fibrino-
gen and fibrin are present in early as well as advanced
atherosclerotic plaques [33], a reduced fibrin clot lysabil-
ity may play a central role in plaque growth and remod-
eling, with important influence in wound healing and
vascular remodeling [34]. In the modern context of
Virchow’s triad [35], the present study might therefore
be of interest, as we report a correlation between CAC
as an abnormality in the vessel wall and a concomitant
reduced clot lysability occurring only in women.
Limitations
Negative ΔAg was recorded in eight participants and
was registered as ΔAg = 0 U, and of these, five partici-
pants had a decrease in Ag ≥ 10 U. However, repeat ana-
lysis after exclusion of all eight participants did not
change our findings. Several studies report difficulties in
assessing CAC progression and definition of subgroups
based on progression in CAC [36–39]. Our subgroup
analysis showed a trend towards decreased fibrin clot
lysability with increasing ΔAg in women compared to
men; however, the number of participants in each group
is limited. Further research in a larger population is
needed to perform subgroup analyses. The hormonal
status in the women was unknown, but no significant
differences in clot lysability between the two age cohorts
in women at both baseline and follow-up were observed.
At the study inclusion, women taking any kind of hor-
mone replacement therapy were excluded. Scanners
from different vendors were used to assess CAC at base-
line and follow-up. However, according to Willemink et
al., both the median relative difference of Ag and the
reclassification rate between the Philips and Toshiba
scanners used in the present study were low [40]. Fifty
study participants were not re-examined at follow-up,
Fig. 3 Clot lysability in women with ΔAgatston score = 0 U (N= 53) and
ΔAgatston score > 0 U (N= 31) at follow-up. Variables are compared
using the unpaired Student’s t test. Mean and SD are indicated in bars
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and clinical information on these participants are not
available. However, these participants were comparable
to the study participants who were re-assessed in terms
of cardiovascular risk factors and Ag at baseline.
Conclusion
Women with progression of CAC over 5 years have
reduced clot lysability compared to men. In addition, these
women have reduced clot lysability compared to women
with no development of CAC. This study suggests that
fibrin clot lysability plays a role in the evolution of CVD.
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